Register your interest
Our NET Patient Forum is an incredible opportunity to connect with our expert NET clinicians, ask questions, and gain valuable insights into current treatments and Clinical Trials.
Date: Tuesday, 28 October, 2025
Time: 5:30pm – 8pm local time (Registration will commence at 5.30pm)
Venue:
Royal North Shore Hospital, Kolling Institute
Cost: Free
There will be plenty of time for questions and discussion at the Forum and you are invited to submit any questions you would like addressed prior to the event. To submit questions or for any further information, please contact info@neuroendocrine.org.au
RSVP by: Thursday, 23rd October.
Light refreshments will be served.
Agenda
| Time | Speaker | Subject |
| 5:30pm | Arrival, register and light refreshments | |
| 6.00pm | Meredith Cummins | Welcome & Acknowledgement of Country |
| 6:05pm | Professor Michael Michael | Updates on Medical Oncology & Clinical trials |
| 6:25pm | A/Prof Grace Kong | Updates on Nuclear Medicine & Clinical Trials |
| 6:45pm | A/Prof Cherie Chiang | Guideline updates for carcinoid crisis in surgery and development of spot urine 5HIAA |
| 7:05pm | Dr Erin Laing | Nutrition |
| 7:20pm | Kate Wakelin | NET Nurse Clinics |
| 7:30pm | Meredith Cummins | NECA update |
| 7:40pm | Q&A | |
| 8:00pm | Close |
Invited guest experts include:
Prof Michael Michael
Medical Oncologist
Professor Michael is a Consultant Gastrointestinal and Neuroendocrine Medical Oncologist, co-chair of the Peter Mac ENETs Centre of Excellence and Medical/Trial lead for the Upper GI Tumour Stream. He graduated from Monash University, completed his medical oncology training at the Peter Mac followed by a 2 year Fellowship at the Princess Margaret Hospital, Ontario Canada.
Returning to Peter Mac as a Consultant Oncologist in 1998, he has now over 25 years of considerable clinical experience in gastrointestinal and neuroendocrine oncology. This is in parallel with the development of clinical and translational research programs and trials in the areas of oncological pharmacology, dose individualisation, pharmacogenomics, novel multi-modality combination therapies both in gastrointestinal and neuroendocrine oncology. Current projects include the identification of novel genetic biomarkers to predict the clinical behaviour of patients with NETs, the establishment of DPYD/UGT1A1 screening programs at Peter Mac and in regional/rural centres, assessing novel chemoradiation therapies (including with immunotherapy) in patients with gastric and rectal cancers, combination treatments to increase the effects of PRRT, and associated translational studies with several laboratory groups based at Peter Mac with the supervision of PhD students.
| A/Prof Grace Kong Nuclear Medicine Physician Grace Kong is a Nuclear Medicine Physician at the Peter MacCallum Cancer Centre (PMCC) in Melbourne Australia, a Clinical Associate Professor at the University of Melbourne, Sir Peter MacCallum Department of Oncology. She is the Co-Chair of the Neuroendocrine Tumour (NET) Unit, a European Neuroendocrine Tumor Society (ENETS) Center of Excellence. She has clinical leadership roles as the Lead of Radionuclide Therapy at PMCC, Chair of the NET multidisciplinary meeting (MDM), and the Nuclear Medicine Lead for the upper gastrointestinal tumour MDM. She was a recipient of the Foundation Discovery Partner Fellowship grant award. Grace graduated from Monash University (Australia) and previously completed a fellowship in PET and radionuclide therapy at the Royal Marsden Hospital in UK. She has broad clinical and research interests in using molecular imaging to characterize cancer, with a focus on advancing theranostics, radionuclide therapy and precision medicine for treating NET, endocrine, prostate and other cancers. She has published multiple practice-changing peer-reviewed articles, particularly in NET and peptide receptor radionuclide therapy (PRRT). She is the CPI / PI for 10+ active prospective national and international collaborative diagnostic and theranostics trials and is a co-investigator of many oncologic studies, particularly in NET, prostate cancer and thyroid cancer. She actively participates in research and education at national and international meetings, is a member of the AANMS committee for Theranostics education. She is engaged in patient education and advocacy as a committee member of Neuroendocrine Cancer Australia. Her vision is to be a lead clinician-researcher, to improve patient outcomes through collaborative prospective clinical and translational research. |
